Altimmune (ALT) Total Non-Current Liabilities (2010 - 2026)

Altimmune (ALT) has 17 years of Total Non-Current Liabilities data on file, last reported at $45.8 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 764.19% year-over-year to $45.8 million in Q1 2026; TTM through Mar 2026 was $45.8 million, a 764.19% increase from a year earlier, with the FY2025 full-year figure at $49.3 million, up 824.65% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $45.8 million, down from $49.3 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for ALT reached as high as $49.3 million in Q4 2025 and fell as low as $4.1 million in Q1 2024.
• Historically, Total Non-Current Liabilities has averaged $16.7 million across 5 years, with a median of $5.8 million in 2024.
• Across the five-year window, Total Non-Current Liabilities slumped 66.41% in 2022 and surged 824.65% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $4.6 million in 2022, then retreated by 3.99% to $4.4 million in 2023, then increased by 21.19% to $5.3 million in 2024, then jumped by 824.65% to $49.3 million in 2025, then dropped by 7.01% to $45.8 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $45.8 million in Q1 2026, $49.3 million in Q4 2025, and $27.1 million in Q3 2025.